| Literature DB >> 18948057 |
Farbod Shojaei1, Napoleone Ferrara.
Abstract
Angiogenesis is critical for growth of many tumor types and the development of anti-angiogenic agents opened a new era in cancer therapy. However, similar to other anti-cancer therapies, inherent/acquired resistance to anti-angiogenic drugs may occur in cancer patients leading to disease recurrence. Recent studies in several experimental models suggest that both tumor and non-tumor (stromal) cell types may be involved in the reduced responsiveness to the treatments. The current review focuses on the role of stromal cells in tumor growth and in refractoriness to anti-VEGF treatment.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18948057 DOI： 10.1016/j.drup.2008.09.001
Source DB: PubMed Journal: Drug Resist Updat ISSN： 1368-7646 Impact factor: 18.500